BioSpace News Archive

Erica Fox has built a career focused on people, teams, technology and impact, with over 25 years of experience spanning HR, analytics, strategy, operations, organizational development and large-scale change management. Erica joined Recursion from Primer.ai, where she served as Chief People Officer. Prior to Primer, Erica spent 15 years at Google leading and contributing to major people and culture initiatives that enabled the company to scale dramatically and successfully. Her Google experience included various leadership roles focused on analytics, employee learning, manager enablement, leadership development, organizational design and teaming.

Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion.

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and Amylyx have seen similarly disappointing results.

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11% average body weight reduction at 12 weeks, with no plateau and a promising safety profile.

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned clinical-stage programs, most notably an antibody-drug conjugate for advanced metastatic colorectal cancer.

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.

The FDA’s guidance on AI in drug development points to potentially life-threatening consequences of the technology, highlighting the importance of providing the regulator with detailed information regarding models’ development and maintenance.

Amid recent backlash stemming from market withdrawals and trial delays, the FDA seeks to further clarify its requirements for confirmatory trials for therapies seeking the shortened path to market.